At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 189 enrolled
Drug / intervention
VEGF Trap-Eye 2.0mg +1 morebiological
Likely dose
VEGF Trap-Eye 2.0mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion
In Brief
A Phase 3 clinical trial evaluating VEGF Trap-Eye 2.0mg and Sham for Macular Edema Secondary to Central Retinal Vein Occlusion. Completed, enrolled 189 participants across 61 sites in 5 countries.
Detailed Summary
This is a phase 3 study to determine the efficacy of VEGF Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Colombia, India, Israel, United States
CollaboratorsBayer
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionOct 2010
Study CompletionApr 2012
TodayJul 2026
First PostedJul 21, 2009
Enrollment StartJul 1, 2009
Primary CompletionOct 1, 2010
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.9 years ago
Interventions
VEGF Trap-Eye 2.0mgbiological
Monthly intravitreal injection out to the Week 24 Primary endpoint
Shamdrug
Monthly sham intravitreal injection out to Week 24 Primary Endpoint